Additional Significant Life Sciences Investments¹

- Bora Pharmaceuticals: Bora Pharmaceuticals, a Taiwanese contract development and manufacturing company, acquired GSK's Mississauga facility and opened its North American flagship facility. Employees at the former GSK site transitioned to Bora Pharmaceuticals. Bora Pharmaceuticals will continue to manufacture, under contract, the existing GSK product line, which includes 50 different products delivered worldwide².
- Roche Canada: Roche Canada made a \$500 million investment over five years to establish a Global Pharma Technical (PT) Operations site bringing up to 500 highly skilled and specialized full-time positions to its Mississauga pharmaceutical headquarters.
- Microbix Biosystems: In 2019, Microbix received a \$2.8 million contribution through FedDev Ontario to scale-up production at its state-of-the-art antigen manufacturing facilities, creating up to 100 highly-skilled jobs in science and manufacturing in Mississauga.
- Eurofins CDMO: Expansion of Eurofins' Drug Product operation capabilities to include fully equipped state-of-the-art pre-formulation and formulation development laboratories, a development suite, multiple GMP manufacturing suites, clinical packaging, and warehousing.
- Biolab Pharma: Biolab received \$2.8 million through the Ontario Jobs and Prosperity
 Fund due to a more considerable overall investment by Biolab, valued at \$57.4 million.
 Mississauga was the company's first international facility outside Brazil. This investment
 included retrofitting a 13,000 sq. ft. research and development (R&D) facility, creating 40
 new highly skilled jobs.
- **Baylis Medical:** Baylis received \$4.22 million in funding through the Ontario Jobs and Prosperity Fund. This investment included expansion into a new state-of-the-art facility to double the company's environmentally controlled rooms and R&D spaces, creating 84 new jobs and retaining 194 positions.

¹ Investments between 2017-2021

² For a minimum of five years